GSK Submits Cervarix? Licence Application To Japan’s Health Authorities
Oct 5th 2007Drug InformationCervical Cancer
GlaxoSmithKline (GSK) announced that it has submitted a licence application for its cervical cancer candidate vaccine Cervarix? to the Japanese Ministry of Health, Labor and Welfare (MHLW). This is the first vaccine for the prevention of cervical cancer to be filed for approval in Japan.GSK’s cervical cancer candidate vaccine is formulated with a novel proprietary adjuvant system called AS04, intended to enhance immune response and increase duration of protection. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
